黄体生成素释放激素激动剂在降低前列腺癌男性睾酮水平方面优于包膜下睾丸切除术:一项随机临床试验的结果
这项随机临床试验纳入58例晚期前列腺癌初治男性,1:1随机接受包膜下睾丸切除术或曲普瑞林22.5 mg每24周 depot 注射,随访48周。曲普瑞林组睾酮水平较手术组低29%(95%CI 17.2-41.7,p<0.001),第12周和第48周睾酮<20 ng/dl的比例更高(97% vs 79%和100% vs 87%,p<0.05),两组肾上腺雄激素降低无差异。
要点
- 曲普瑞林24周depot注射较包膜下睾丸切除术降低睾酮29%(95%CI 17.2-41.7,p<0.001)。
- 第12周和第48周曲普瑞林组睾酮<20 ng/dl比例分别为97%和100%,手术组为79%和87%(p<0.05)。
- 两组肾上腺雄激素降低无差异,作者称这是首个显示手术与药物去势睾酮水平差异的随机研究。
核心结论
- 24周depot曲普瑞林注射较包膜下睾丸切除术显著降低睾酮水平。
- 据作者所知,这是首个证明手术与药物去势对睾酮水平存在治疗效应差异的随机研究。
研究设计与样本
- 随机临床试验,纳入58例在丹麦Herlev和Gentofte大学医院于2013年9月至2015年3月诊断的晚期前列腺癌初治男性。
- 参与者1:1随机分配至包膜下睾丸切除术或曲普瑞林22.5 mg每24周depot注射,随访48周。
- 治疗前及第12、24、48周用液相色谱-串联质谱法测定雄激素状态,组间激素水平差异用纵向Tobit回归分析。
主要发现
- 曲普瑞林注射较包膜下睾丸切除术降低睾酮29%(95%CI 17.2-41.7,p<0.001)。
- 第12周曲普瑞林组睾酮<20 ng/dl比例为97%,手术组为79%(p<0.05)。
- 第48周曲普瑞林组睾酮<20 ng/dl比例为100%,手术组为87%(p<0.05)。
- 两组肾上腺雄激素降低未检测到差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Recent evidence suggests that reaching the lowest achievable levels of testosterone with androgen deprivation therapy delays disease progression and increases overall survival in men with advanced prostate cancer. The aim of this analysis was to compare posttreatment serum testosterone levels between patients undergoing subcapsular orchiectomy and patients treated with the luteinizing hormone-releasing hormone agonist triptorelin. MATERIALS AND METHODS: In this randomized clinical trial we included 58 consecutive hormone naïve men diagnosed with advanced prostate cancer at Herlev and Gentofte University Hospital, Herlev, Denmark from September 2013 to March 2015. Followup was 48 weeks. Participants were randomly assigned 1:1 to subcapsular orchiectomy or triptorelin 22.5 mg given as 24-week depot injections. Androgen status was measured by liquid chromatography-tandem mass spectrometry prior to treatment and after 12, 24 and 48 weeks. Between group differences in achieved hormone levels were analyzed by longitudinal Tobit regression. RESULTS: Triptorelin injections resulted in 29% lower testosterone levels (95% CI 17.2-41.7) compared to subcapsular orchiectomy (p <0.001). A significantly higher proportion of men receiving triptorelin had testosterone levels less than 20 ng/dl at 12 and 48 weeks compared to men undergoing orchiectomy (97% vs 79% and 100% vs 87%, respectively, p <0.05). There was no detectable difference in the adrenal androgen reduction between the treatment groups. CONCLUSIONS: The use of 24-week depot triptorelin injections results in significantly lower testosterone levels compared to subcapsular orchiectomy. To our knowledge this is the first randomized study to demonstrate a difference in treatment effect between surgical and medical castration on testosterone levels.
引用
- Østergren PB, Kistorp C, Fode M, et al. Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial. J Urol. 2016. PMID: 27939836. doi:10.1016/j.juro.2016.12.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。